Similarly, development of a prostate-specific membrane antigen (PSMA)-specific antibody response was associated with improvement in overall survival after treatment with prostate cancer GVAX combined with ipilimumab (anti-CTLA-4) [51]. Here, FOLH1 is linked to prostate cancer.